DESTINY-Endometrial01: Study on Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab for First-Line Treatment of HER2-Positive Endometrial Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of epithelial endometrial carcinoma (except sarcomas, but carcinosarcomas are allowed).
• Have advanced (Stage III/IV) or first recurrent endometrial cancer after surgery or biopsy.
• Cancer must show HER2 expression (3+ or 2+) and be mismatch repair proficient (pMMR).
• Provide a tumor sample for testing.
• Have not received first-line systemic anticancer therapy, except possibly one prior line of chemotherapy if the cancer returned 6 months after treatment.
• Have not been treated with certain types of cancer drugs before.
• May have had prior radiation therapy for endometrial cancer.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have a heart function of at least 50%.
• Have adequate organ and bone marrow function.

Exclusion Criteria

• History of organ transplant.
• Have uncontrolled illnesses or active infections.
• Have spinal cord compression or active brain metastases.
• Have had a heart attack in the last 6 months or have serious heart conditions.
• Have a history of lung disease that required steroids or current lung issues.
• Have significant lung illnesses or autoimmune disorders affecting the lungs.
• Have had a complete lung removal.
• Have active autoimmune or inflammatory disorders needing chronic treatment.
• Have active infections like tuberculosis, uncontrolled HIV, or hepatitis B or C (unless controlled with treatment).
• Are receiving other cancer treatments without a proper break before starting the study.